{"id":12664,"date":"2019-03-28T22:14:56","date_gmt":"2019-03-28T21:14:56","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=12664"},"modified":"2019-04-02T22:22:28","modified_gmt":"2019-04-02T20:22:28","slug":"ocello-announces-two-year-agreement-with-merus","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/","title":{"rendered":"OcellO announces two year agreement with Merus"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">OcellO, a Contract Research Organisation offering 3D\ncell based assay services for drug discovery to the pharmaceutical industry, has\nentered an agreement to provide <em>in vitro<\/em> research services to Merus, a\nclinical-stage immuno-oncology company developing innovative bispecific\nantibody therapeutics, for Merus\u2019 MCLA-158 Biclonics\u00ae program and other\nundisclosed Biclonics\u00ae discovery programs.&nbsp; <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pursuant to the agreement, OcellO will provide \u20ac1\nmillionof<em> in vitro<\/em> research services to Merus over a period of\ntwo years. OcellO will also utilize its 3D immune-oncology co-culture screening\ntechnology to support other undisclosed Merus Biclonics\u00ae discovery programs. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merus is developing MCLA-158 in Phase 1 in patients\nwith solid tumors with an initial focus on metastatic colorectal cancer.&nbsp;\nMCLA-158 is designed to bind to cancer stem cells expressing leucine-rich\nrepeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor\nreceptors (EGFR). \u201cWith this new commitment Merus looks forward to extending\nits long-standing productive relationship with the OcellO team\u201d said Mark\nThrosby, CSO of Merus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis significant service agreement between OcellO and Merus enables OcellO to further invest in its technology platform \u2013 particularly for immune-oncology drug discovery \u2013 to meet the needs of Merus and other companies in the immune-oncology space\u201d said Leo Price, CEO of OcellO. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <a href=\"https:\/\/ocello.nl\/press-release\/\"><strong>OcellO<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>OcellO, a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, has entered an agreement to provide in vitro research services to Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, for Merus\u2019 MCLA-158 Biclonics\u00ae program and other undisclosed Biclonics\u00ae discovery programs.&nbsp; Pursuant to the agreement, OcellO [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39,43],"tags":[],"class_list":["post-12664","post","type-post","status-publish","format-standard","hentry","category-gezondheid","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OcellO announces two year agreement with Merus - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OcellO announces two year agreement with Merus - hollandbio\" \/>\n<meta property=\"og:description\" content=\"OcellO, a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, has entered an agreement to provide in vitro research services to Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, for Merus\u2019 MCLA-158 Biclonics\u00ae program and other undisclosed Biclonics\u00ae discovery programs.&nbsp; Pursuant to the agreement, OcellO [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-28T21:14:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-02T20:22:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"OcellO announces two year agreement with Merus\",\"datePublished\":\"2019-03-28T21:14:56+00:00\",\"dateModified\":\"2019-04-02T20:22:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/\"},\"wordCount\":204,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/\",\"name\":\"OcellO announces two year agreement with Merus - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-03-28T21:14:56+00:00\",\"dateModified\":\"2019-04-02T20:22:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/ocello-announces-two-year-agreement-with-merus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OcellO announces two year agreement with Merus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OcellO announces two year agreement with Merus - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/","og_locale":"en_US","og_type":"article","og_title":"OcellO announces two year agreement with Merus - hollandbio","og_description":"OcellO, a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, has entered an agreement to provide in vitro research services to Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, for Merus\u2019 MCLA-158 Biclonics\u00ae program and other undisclosed Biclonics\u00ae discovery programs.&nbsp; Pursuant to the agreement, OcellO [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/","og_site_name":"hollandbio","article_published_time":"2019-03-28T21:14:56+00:00","article_modified_time":"2019-04-02T20:22:28+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"OcellO announces two year agreement with Merus","datePublished":"2019-03-28T21:14:56+00:00","dateModified":"2019-04-02T20:22:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/"},"wordCount":204,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/","name":"OcellO announces two year agreement with Merus - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-03-28T21:14:56+00:00","dateModified":"2019-04-02T20:22:28+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/ocello-announces-two-year-agreement-with-merus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"OcellO announces two year agreement with Merus"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=12664"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=12664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=12664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=12664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}